Self-Sampling As a Plausible Alternative to Screen Cervical Cancer Precursor Lesions in a Population with Low Adherence to Screening: A Systematic Review
Overview
Authors
Affiliations
Background: Cervical cancer is the fourth most common cancer in the world. A raised incidence and mortality parallel a low participation rate in screening, namely screening in poor countries and among specific populations of developed countries. Cervical or vaginal self-sampling may increase adherence to screening due to its low costs and elevated sensibility and specificity. Our main goal was to compare self-sampling with physician sampling and to evaluate the participation rate of women formerly non-adherent to cervical cancer screening.
Study Design: We identified relevant studies from PubMed. Studies were eligible for inclusion if they fulfilled the following criteria: women aged between 16 and 80 years, poor and developed countries that use self-sampling, women with a low participation rate in screening and studies published since 2013. After fully reading the articles, data were extracted to an Excel sheet to -display all relevant information in an organized manner. -Results: We identified 18 studies, which altogether enrolled 22,118 women. Self-sampling and physician sampling are quite similar regarding the HPV detection rate. Women have a low participation rate mainly because of limited access to health services, religious and culture beliefs, and lack of time due to several demanding tasks in daily life. Self-sampling shows a significant increase in acceptability and preference compared to physician sampling.
Conclusion: Self-sampling is a reliable method to involve women in opportunistic or organized screening programs for cervical cancer prevention.
Le Goff J, Le Duc-Banaszuk A, Lefeuvre C, Pivert A, Ducancelle A, De Pauw H Cancers (Basel). 2024; 16(11).
PMID: 38893189 PMC: 11171172. DOI: 10.3390/cancers16112066.
Wong A, Morgis R, Entenman J, Ramirez S, Hays A, Wright T Womens Health Rep (New Rochelle). 2024; 5(1):259-266.
PMID: 38516651 PMC: 10956530. DOI: 10.1089/whr.2024.0004.
Moss J, Entenman J, Stoltzfus K, Liao J, Onega T, Reiter P JNCI Cancer Spectr. 2023; 8(1).
PMID: 38060284 PMC: 10868381. DOI: 10.1093/jncics/pkad103.
Le Goff J, Le Duc-Banaszuk A, Lefeuvre C, Pivert A, Ducancelle A, De Pauw H Cancers (Basel). 2023; 15(21).
PMID: 37958337 PMC: 10648237. DOI: 10.3390/cancers15215163.
Marques P, Geraldes M, Gama A, Heleno B, Dias S BMC Womens Health. 2023; 23(1):52.
PMID: 36759781 PMC: 9909634. DOI: 10.1186/s12905-023-02198-2.